Journal of Clinical Endocrinology & Metabolism, Vol 65, 671-678, Copyright © 1987 by Endocrine Society

ARTICLES

Growth hormone treatment in short children: relationship between growth and serum insulin-like growth factor I and II levels

K Albertsson-Wikland and K Hall
Department of Pediatrics II, University of Goteborg, Sweden.

Thirty-one children who were short but not GH deficient, whose serum GH responses to provocative tests were normal, and whose spontaneous GH secretion was low received daily sc injections of human GH (Crescormon; 0.1 IU/kg BW) for 1 yr. Their initial serum insulin-like growth factor I (IGF-I) and IGF-II responses to GH were compared with their 1-yr growth response to therapy. In the prepubertal group (n = 18) the growth rate of all but two children increased 3.4 +/- 0.2 (+/- SEM) cm (from 4.1 +/- 0.2 to 7.5 +/- 0.3 cm/yr). The mean increment in the growth rate of the pubertal group was 5.2 +/- 0.5 cm. In both groups the growth increase was strongly correlated with both the percent increase in serum IGF-I and the percent increase in serum IGF-II during the first 10 days of treatment. No correlation was found between the basal growth rate and basal serum IGF-I or IGF-II levels. In the prepubertal group of children, both the percent increase in serum IGF-I levels in response to GH and the age at start of treatment were predictors of long term growth. We conclude that this subgroup of normal short children with low spontaneous GH secretion and high percent increase in serum IGF values benefits from GH treatment with an increased growth rate.

This article has been cited by other articles:

				M. Nishikawa-Ogawa, H. Wanibuchi, K. Morimura, A. Kinoshita, T. Nishikawa, S. Hayashi, Y. Yano, and S. Fukushima N-acetylcysteine and S-methylcysteine inhibit MeIQx rat hepatocarcinogenesis in the post-initiation stage Carcinogenesis, May 1, 2006; 27(5): 982 - 988. [Abstract] [Full Text] [PDF]

				C. K. Buckway, K. A. Selva, K. L. Pratt, E. Tjoeng, J. Guevara-Aguirre, and R. G. Rosenfeld Insulin-Like Growth Factor Binding Protein-3 Generation as a Measure of GH Sensitivity J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4754 - 4765. [Abstract] [Full Text] [PDF]

				B. Kristrom, C. Jansson, S. Rosberg, and K. Albertsson-Wikland Growth Response to Growth Hormone (GH) Treatment Relates to Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Short Children with Various GH Secretion Capacities J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2889 - 2898. [Abstract] [Full Text] [PDF]

				M. Thoren, A. Hilding, R. C. Baxter, M. Degerblad, I.-L. Wivall-Helleryd, and K. Hall Serum Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-1 and -3, and the Acid-Labile Subunit as Serum Markers of Body Composition during Growth Hormone (GH) Therapy in Adults with GH Deficiency J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 223 - 228. [Abstract] [Full Text] [PDF]